Oppenheimer Raises Teva Pharmaceuticals Price Target to $50

Investment firm Oppenheimer has upgraded its rating on Teva Pharmaceuticals to 'Outperform' and set a new price target of $50 per share, representing a potential 26% upside from its recent closing price of approximately $39.60. This new target places Teva at the high end of analyst expectations, which currently range from $40 to $50.

Oppenheimer's optimistic outlook is based on Teva entering a new phase of its turnaround strategy under CEO Richard Francis. While previous efforts focused on debt reduction, stabilizing generic operations, and building growth engines, the company's three key innovative drugs, Osterdo, Ajovy, and Uzedy, are now becoming increasingly significant contributors to revenue and profit. Teva projects these three drugs will generate combined revenues of about $3.7 billion in 2026, a 17% increase from the previous year. In the second quarter alone, they collectively brought in over $1 billion, with Osterdo at $696 million, Ajovy at $244 million, and Uzedy at $77 million, all showing substantial year-over-year growth.

The increasing reliance on innovative drugs, rather than traditional generics, is also improving Teva's profit margins. The company reported a gross profit margin of 52% in the second quarter, up from 50.3% in the same period last year, and a non-GAAP gross margin of 55.4% compared to 54.6%. Teva attributes this improvement to the strong performance of Osterdo and Ajovy and a more favorable product mix. Oppenheimer sees this trend as a key driver for future profit growth.

Furthermore, Teva is progressing with its efficiency program, aiming for a net cumulative savings of approximately $700 million by 2027 and a non-GAAP operating profit margin of around 30% in the same year. The company is also building a robust pipeline beyond its current key drugs. This includes a long-acting olanzapine injection for schizophrenia expected in the U.S. in late 2026, the acquisition of Emalex for Tourette syndrome treatment, and ongoing development of treatments for vitiligo and inflammatory diseases like Crohn's and colitis in partnership with Sanofi.

Teva's biosimilars division is also poised for growth, with a target of $800 million in revenue by 2027 from a portfolio expected to include 18 products. This diversification aims to offset the continued pressure from traditional generics, which saw a 15% revenue decline in the second quarter, largely due to increased competition for generic Revlimid in the U.S. Oppenheimer believes this combination of growth in existing innovative drugs, margin improvement, and new product launches could support not only increased profits but also a higher valuation multiple for Teva.